KBKevin K. Brown

Kevin K. Brown

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kevin K. Brown has a total of 163 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Interstitial Lung Abnormality

    by Zein Kattih, Brett Bade, Hiroto Hatabu, Kevin Brown, Joseph Parambil, Akinori Hata, Peter J. Mazzone, Stephen Machnicki, Dominick Guerrero, Muhammad Qasim Chaudhry, et al.


  • Quantitative High-Resolution Computed Tomography Predicts Progressive Pulmonary Fibrosis

    by M. Koslow, D. Baraghoshi, M. Strand, J. Solomon, J.J. Swigris, D.A. Lynch, M.P. Mohning, Z.X. Yunt, R. Keith, E. Fernandez Perez, et al.

  • Somatic Mutations of MUC5B Within Lung Tissue in Idiopathic Pulmonary Fibrosis

    by J.H. Yun, M.A.W. Khan, K. Krone, A.J. Ghosh, B.D. Hobbs, P. Castaldi, C.P. Hersh, P. Miller, F.C. Sciurba, L. Barwick, et al.

  • Rheumatoid Arthritis and the Lungs

    by Joshua J. Solomon, Kevin Brown, Mary Kristen Demoruelle

  • Interstitial Pneumonia with Autoimmune Features

    by Amen Sergew, Aryeh Fischer, Kevin Brown

  • Open Access

    Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial

    by Yoshikazu Inoue, Athol U. Wells, Jin Woo Song, Zuojun Xu, Hideya Kitamura, Takafumi Suda, Masaki Okamoto, Heiko Müller, Carl Coeck, Klaus B. Rohr, et al.

    Background and Objective: In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity (FVC) with an adverse event profile characterized mainly by gastrointestinal events. We analysed the effects of nintedanib in the subset of Asian subjects.Methods: Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis who had shown progression of ILD at any time within the prior 24 months despite management deemed appropriate in clinical practice were randomized to receive nintedanib or placebo. We analysed the rate of decline in FVC (ml/year) over 52 weeks in all Asian subjects and in Asian subjects with a usual interstitial pneumonia (UIP)‐like fibrotic pattern on high‐resolution computed tomography (HRCT).Results: One hundred sixty‐four subjects in the INBUILD trial were of Asian race. The rate of decline in FVC (ml/year) over 52 weeks in this subgroup was −116.8 in the nintedanib group and −207.9 in the placebo group (difference: 91.0 [95% CI: 8.1, 173.9]; nominal p = 0.03). In Asian subjects with a UIP‐like fibrotic pattern on HRCT, the rate of decline in FVC (ml/year) over 52 weeks was −130.1 in the nintedanib group and −224.2 in the placebo group (difference: 94.1 [5.5, 182.7]; nominal p = 0.04). Adverse events led to treatment discontinuation in 19.0% of the nintedanib group and 13.8% of the placebo group.Conclusion: In Asian patients with progressive fibrosing ILDs, nintedanib reduced the rate of decline in FVC with adverse events that were manageable for most patients.


  • Open Access

    Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases

    by Kevin K. Brown, Yoshikazu Inoue, Kevin R. Flaherty, Fernando J. Martinez, Vincent Cottin, Francesco Bonella, Stefania Cerri, Sonye K. Danoff, Stephane Jouneau, Rainer‐Georg Goeldner, et al.

    Background and objective: Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from the INPULSIS trials in subjects with idiopathic pulmonary fibrosis (IPF) and the INBUILD trial in subjects with other progressive fibrosing ILDs to assess relationships between demographic/clinical variables and mortality.Methods: The relationships between baseline variables and time‐varying covariates and time to death over 52 weeks were analysed using pooled data from the INPULSIS trials and, separately, the INBUILD trial using a Cox proportional hazards model.Results: Over 52 weeks, 68/1061 (6.4%) and 33/663 (5.0%) subjects died in the INPULSIS and INBUILD trials, respectively. In the INPULSIS trials, a relative decline in forced vital capacity (FVC) >10% predicted within 12 months (hazard ratio [HR] 3.77) and age (HR 1.03 per 1‐year increase) were associated with increased risk of mortality, while baseline FVC % predicted (HR 0.97 per 1‐unit increase) and diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 0.77 per 1‐unit increase) were associated with lower risk. In the INBUILD trial, a relative decline in FVC >10% predicted within 12 months (HR 2.60) and a usual interstitial pneumonia‐like fibrotic pattern on HRCT (HR 2.98) were associated with increased risk of mortality, while baseline DLCO % predicted (HR 0.95 per 1‐unit increase) was associated with lower risk.Conclusion: These data support similarity in the course of lung injury between IPF and other progressive fibrosing ILDs and the value of FVC decline as a predictor of mortality.


  • Top Cited Papers
    Open Access

    Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial

    by Kevin R. Flaherty, Athol U. Wells, Vincent Cottin, Anand Devaraj, Yoshikazu Inoue, Luca Richeldi, Simon L.F. Walsh, Martin Kolb, Dirk Koschel, Teng Moua, et al.

    Background The primary analysis of the INBUILD trial showed that in subjects with progressive fibrosing interstitial lung diseases (ILDs), nintedanib slowed the decline in forced vital capacity (FVC) over 52 weeks. We report the effects of nintedanib on ILD progression over the whole trial. Methods Subjects with fibrosing ILDs other than idiopathic pulmonary fibrosis, who had ILD progression within the 24 months before screening despite management deemed appropriate in clinical practice, were randomised to receive nintedanib or placebo. Subjects continued on blinded randomised treatment until all subjects had completed the trial. Over the whole trial, mean±sd exposure to trial medication was 15.6±7.2 and 16.8±5.8 months in the nintedanib and placebo groups, respectively. Results In the nintedanib (n=332) and placebo (n=331) groups, respectively, the proportions of subjects who had ILD progression (absolute decline in FVC ≥10% predicted) or died were 40.4% and 54.7% in the overall population (hazard ratio (HR) 0.66, 95% CI 0.53–0.83; p=0.0003) and 43.7% and 55.8% among subjects with a usual interstitial pneumonia (UIP)-like fibrotic pattern on high-resolution computed tomography (HRCT) (HR 0.69, 95% CI 0.53–0.91; p=0.009). In the nintedanib and placebo groups, respectively, the proportions who had an acute exacerbation of ILD or died were 13.9% and 19.6% in the overall population (HR 0.67, 95% CI 0.46–0.98; p=0.04) and 15.0% and 22.8% among subjects with a UIP-like fibrotic pattern on HRCT (HR 0.62, 95% CI 0.39–0.97; p=0.03). Conclusion Based on data from the whole INBUILD trial, nintedanib reduced the risk of events indicating ILD progression. In patients with fibrosing ILDs other than IPF who had shown progression of ILD within the prior 2 years, events indicating further progression occurred frequently. Over a 16-month period, nintedanib reduced the risk of such events versus placebo.https://bit.ly/3yiZXnS


  • Open Access

    Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”

    by Kevin K. Brown, Rozsa Schlenker-Herceg, Athol U. Wells

    No set of criteria will cover all patients, but the inclusion criteria used in the INBUILD trial were effective at identifying a population of patients with progressive ILDhttps://bit.ly/3mKkzzi